# Targanta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/targanta-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.targanta.com
- Total disclosed funding: $70M
- Latest round: Series C (Feb 9, 2007)
- Investors on record: 7

## About

Targanta Therapeutics Inc. is a biotechnology company focused on developing innovative antibacterial treatments, with a key emphasis on its antibiotic Oritavancin to combat resistant strains of Gram-positive bacteria.Founded in 1997, Targanta Therapeutics Inc. operates out of Cambridge, US, and specializes in antibacterial treatments. The company underwent a significant change when it was acquired by The Medicines Co. in February 2009, following its IPO where it raised USD 57.5 mn by pricing 5.75 million shares at USD 10.00 each in October 2007. The current CEO is Mark Leuchtenberger.Targanta Therapeutics specializes in the development of innovative antibacterial treatments, primarily focusing on the antibiotic Oritavancin. Oritavancin is designed to combat resistant strains of Gram-positive bacteria, addressing critical healthcare challenges such as skin and soft tissue infections, as well as severe infections caused by resistant organisms. The effectiveness of Oritavancin has been demonstrated in various preclinical models, including studies on anthrax and osteomyelitis, thus highlighting its versatile application in treating serious infections. Targanta serves healthcare providers and pharmaceutical distributors primarily within the United States and Europe, enhancing the effectiveness of antibacterial therapies against emerging resistant pathogens.Targanta Therapeutics generates revenue through partnerships and collaborations with healthcare organizations and pharmaceutical companies focused on antibacterial solutions. Transaction structures typically involve agreements where Targanta supplies its flagship antibiotic, Oritavancin, to healthcare providers and distributors, who then offer the treatment to end-users such as hospitals and clinics. These transactions may include bulk purchasing agreements or licensing arrangements for the use of its proprietary technology in developed treatments. Targanta reported an EBITDA of USD -62.46 mn for the year 2007.Targanta Therapeutics plans to leverage its recent IPO funding of USD 57.5 mn from October 2007 to further develop its antibiotic Oritavancin and explore new therapeutic applications. The company aims to expand into additional markets in Europe and Asia by 2009, targeting regions with rising resistance to bacterial infections. The funding is expected to support research and development initiatives for upcoming product launches, enhancing Targanta's position in the antibacterial treatment landscape.

## Funding rounds

- Series C, Feb 9, 2007, $70M — OrbiMed Advisors, Seaflower Ventures, VenGrowth Capital Partners, Skyline Ventures, Radius Ventures, Canadian Medical Discoveries Fund Inc., Brookside Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Seaflower Ventures (https://capitalatlas.ai/funds/seaflower-ventures) — Series C
- VenGrowth Capital Partners (https://capitalatlas.ai/funds/vengrowth-capital-partners) — Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series C
- Radius Ventures (https://capitalatlas.ai/funds/radius-ventures) — Series C
- Canadian Medical Discoveries Fund Inc. — Series C
- Brookside Capital — Series C